Breaking News Instant updates and real-time market news.

PFE

Pfizer

$42.41

0.45 (1.07%)

12:56
02/17/19
02/17
12:56
02/17/19
12:56

Pfizer, EMD Serono announce publication of Phase 3 data for BAVENCIO plus INLYTA

Merck KGaA, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, and Pfizer announced the publication of results from an interim analysis of the pivotal JAVELIN Renal 101 trial online in the New England Journal of Medicine. The combination of BAVENCIO and INLYTA significantly extended median progression-free survival by more than 5 months compared with SUTENT as a first-line treatment for patients with advanced renal cell carcinoma, irrespective of PD-L1 expression. Further, the objective response rate was doubled with BAVENCIO+INLYTA versus SUTENT in this population. The study is continuing for the other primary endpoint of overall survival. Additional data presented at the 2019 Genitourinary Cancers Symposium reinforce the consistency of the PFS and ORR results across patient subgroups, including patients with favorable, intermediate and poor prognoses as well as those with PD-L1-positive or negative tumors. In subgroup analyses, approximately two-thirds of patients with favorable risk achieved a complete or partial response with BAVENCIO+INLYTA. Median PFS for these patients is not yet estimable. BAVENCIO+INLYTA also extended median PFS2, defined as the time from randomization to disease progression on next-line therapy and increased median duration of response by more than four months in the overall population. Adverse events of grade 3 or higher during treatment occurred in 71.2% of patients in the BAVENCIO+INLYTA arm and 71.5% in the SUTENT arm. In the combination arm, 9.0% of patients experienced grade 3 or higher immune-related adverse events. Grade 5 events occurred in three patients in the BAVENCIO+INLYTA arm and in one patient in the SUTENT arm. There were fewer discontinuations due to adverse events that occurred during treatment with BAVENCIO+INLYTA, compared with SUTENT. On February 11, 2019, the alliance announced that the U.S. Food and Drug Administration accepted for Priority Review the supplemental Biologics License Application for BAVENCIO in combination with INLYTA for patients with advanced RCC. The application has been given a target action date in June 2019. A supplemental application for BAVENCIO+INLYTA in unresectable or metastatic RCC was submitted in Japan on January 30, 2019. In December 2017, the FDA granted Breakthrough Therapy Designation for BAVENCIO in combination with INLYTA for treatment-naive patients with advanced RCC. Despite available therapies, the outlook for patients with advanced RCC remains poor.

  • 20

    Feb

  • 18

    May

PFE Pfizer
$42.41

0.45 (1.07%)

01/31/19
01/31/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Neutral at Credit Suisse and to Buy from Hold at Argus. 2. Tiffany (TIF) upgraded to Overweight from Neutral at Atlantic Equities with analyst Daniela Nedialkova saying the pullback has been largely driven by macro concerns while fundamentals of the brand are strong and preliminary FY19 guidance is conservative. 3. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 4. Geron (GERN) upgraded to Buy from Neutral at B. Riley FBR with analyst George Zavoico saying he believes investors should focus on the pivotal Phase III trial of imetelstat. 5. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Dana Telsey saying the company's improving sakes, combined with ongoing margin expansion, should bolster its earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/19
ARGS
01/31/19
UPGRADE
Target $55
ARGS
Pfizer upgraded to Buy from Hold at Argus
Argus analyst David Toung upgraded Pfizer (PFE) to Buy with a price target of $55, saying he anticipates an upward revenue inflection point in 2021 after flat sales in the second half of 2019 and first half of 2020. After cycling through Lyrica loss of exclusivity over the next year, the analyst anticipates Pfizer to benefit from optimized portfolio of assets as it completes its consumer healthcare business joint venture with GlaxoSmithKline (GSK). Toung adds that while he does not "expect major transformational deals", he does see the management pursuing "acquisitions and divestitures that improve long-term profitability".
01/31/19
01/31/19
UPGRADE
Target $47

Outperform
Pfizer upgraded to Outperform on new product story at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Pfizer to Outperform from Neutral and raised his price target on the shares to $47 from $45. The analyst notes that Pfizer has been working through a dark period with extensive patent expirations that have hampered the company's ability to grow, but that period is now nearing an end. Further, the analyst believes the company's new product story with multiple marketed and pipeline assets may be underappreciated.
01/31/19
ARGS
01/31/19
UPGRADE
ARGS
Buy
Pfizer upgraded to Buy from Hold at Argus

TODAY'S FREE FLY STORIES

BA

Boeing

$372.69

-3.72 (-0.99%)

, LMT

Lockheed Martin

$298.95

3.04 (1.03%)

16:50
03/21/19
03/21
16:50
03/21/19
16:50
Hot Stocks
Sikorsky-Boeing helicopter achieves first flight »

The Sikorsky-Boeing…

BA

Boeing

$372.69

-3.72 (-0.99%)

LMT

Lockheed Martin

$298.95

3.04 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 28

    May

VOYA

Voya Financial

$50.34

0.11 (0.22%)

16:50
03/21/19
03/21
16:50
03/21/19
16:50
Conference/Events
Voya Financial management to meet with Evercore ISI »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 23

    May

BIIB

Biogen

$226.71

-93.76 (-29.26%)

, AAPL

Apple

$195.07

6.93 (3.68%)

16:48
03/21/19
03/21
16:48
03/21/19
16:48
On The Fly
Fly Intel: Wall Street's top stories for Thursday »

Stocks did not show much…

BIIB

Biogen

$226.71

-93.76 (-29.26%)

AAPL

Apple

$195.07

6.93 (3.68%)

MU

Micron

$44.00

3.92 (9.78%)

F

Ford

$8.69

0.18 (2.12%)

AMZN

Amazon.com

$1,818.45

21.09 (1.17%)

SNAP

Snap

$11.02

0.08 (0.73%)

LEVI

Levi Strauss

$22.42

(0.00%)

WMT

Walmart

$99.05

0.4 (0.41%)

SRNE

Sorrento Therapeutics

$5.20

1.71 (49.00%)

DRI

Darden

$116.11

7.485 (6.89%)

DXCM

DexCom

$142.13

-3.94 (-2.70%)

CSIQ

Canadian Solar

$19.27

-4.27 (-18.14%)

GES

Guess

$19.33

-2.77 (-12.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 25

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 04

    Apr

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 01

    May

  • 16

    May

  • 28

    May

  • 24

    Jul

  • 23

    Oct

  • 21

    Mar

GG

Goldcorp

$11.17

0.13 (1.18%)

, NEM

Newmont Mining

$34.32

0.44 (1.30%)

16:47
03/21/19
03/21
16:47
03/21/19
16:47
Hot Stocks
Paulson & Co. opposes terms of Newmont's proposed acquisition of Goldcorp »

Paulson & Co, a…

GG

Goldcorp

$11.17

0.13 (1.18%)

NEM

Newmont Mining

$34.32

0.44 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Apr

CBAN

Colony Bankcorp

$16.70

-0.04 (-0.24%)

16:45
03/21/19
03/21
16:45
03/21/19
16:45
Hot Stocks
LBC shareholders approve merger with Colony Bankcorp »

Colony Bankcorp, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:42
03/21/19
03/21
16:42
03/21/19
16:42
Conference/Events
CLSA Asia consumer analyst to hold a group luncheon »

Head of Asia Consumer…

16:38
03/21/19
03/21
16:38
03/21/19
16:38
Conference/Events
CLSA Asia gaming analyst to hold a group luncheon »

Jonathan Galligan, Head…

16:37
03/21/19
03/21
16:37
03/21/19
16:37
General news
Fed Balance Sheet Level data reported »

Week of 3/20 Fed Balance…

EXPE

Expedia

$124.13

1.56 (1.27%)

16:37
03/21/19
03/21
16:37
03/21/19
16:37
Hot Stocks
Expedia says Scott Rudin resigned from board »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTA

Ulta Beauty

$335.02

4.31 (1.30%)

16:37
03/21/19
03/21
16:37
03/21/19
16:37
Hot Stocks
Ulta Beauty director Dennis Eck sells 15K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$45.60

-0.03 (-0.07%)

16:35
03/21/19
03/21
16:35
03/21/19
16:35
Initiation
Smartsheet initiated at DA Davidson »

Smartsheet initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Apr

KVHI

KVH Industries

$10.71

-0.11 (-1.02%)

16:35
03/21/19
03/21
16:35
03/21/19
16:35
Hot Stocks
KVH Industries expands HTS Maritime Network for entire Pacific Ocean region »

KVH Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLW

Clearwater Paper

$21.20

-0.135 (-0.63%)

, ITRI

Itron

$51.15

0.64 (1.27%)

16:32
03/21/19
03/21
16:32
03/21/19
16:32
Hot Stocks
Clearwater Paper names Robert Hrivnak as CFO, succeeding John Hertz »

Clearwater Paper (CLW)…

CLW

Clearwater Paper

$21.20

-0.135 (-0.63%)

ITRI

Itron

$51.15

0.64 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$18.77

-0.24 (-1.26%)

16:32
03/21/19
03/21
16:32
03/21/19
16:32
Initiation
Stifel starts Amarin with Buy rating, sees 'robust' growth for Vascepa »

Stifel analyst Derek…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

MTW

Manitowoc

$17.11

0.1 (0.59%)

16:31
03/21/19
03/21
16:31
03/21/19
16:31
Hot Stocks
Manitowoc settles action seeking damages for trade secret misappropriation »

The Manitowoc Company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
03/21/19
03/21
16:30
03/21/19
16:30
Options
Preliminary option volume of 20.3M today »

Preliminary option volume…

CEO

Cnooc

$180.04

1.415 (0.79%)

16:29
03/21/19
03/21
16:29
03/21/19
16:29
Downgrade
Cnooc rating change at CLSA »

Cnooc downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRZN

Horizon Technology

$12.55

0.22 (1.78%)

16:24
03/21/19
03/21
16:24
03/21/19
16:24
Syndicate
Horizon Technology files to sell 2M shares of common stock »

The joint-lead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGL

Sol-Gel Technologies

$7.00

(0.00%)

16:22
03/21/19
03/21
16:22
03/21/19
16:22
Earnings
Sol-Gel Technologies reports FY18 loss $32.2M versus $31.6M last year »

Reports FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

  • 04

    Apr

DCP

DCP Midstream

$33.96

0.835 (2.52%)

16:20
03/21/19
03/21
16:20
03/21/19
16:20
Initiation
DCP Midstream initiated at Mizuho »

DCP Midstream initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$88.05

1.3597 (1.57%)

16:20
03/21/19
03/21
16:20
03/21/19
16:20
Hot Stocks
Breaking Hot Stocks news story on Nike »

Nike down 3.4% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

CTAS

Cintas

$208.00

2.78 (1.35%)

16:20
03/21/19
03/21
16:20
03/21/19
16:20
Hot Stocks
Cintas reports Q3 organic revenue growth up 6% »

Reports Q3 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
03/21/19
03/21
16:20
03/21/19
16:20
Options
Closing CBOE SPX and VIX Index summary for March 21st »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$18.77

-0.24 (-1.26%)

16:19
03/21/19
03/21
16:19
03/21/19
16:19
Initiation
Amarin initiated at Stifel »

Amarin initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

NNDM

Nano Dimension

$0.77

0.012 (1.59%)

16:19
03/21/19
03/21
16:19
03/21/19
16:19
Hot Stocks
Nano Dimension receives Nasdaq non-compliance notification »

Nano Dimension announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.